Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Hemay022+AIDrug: Lapatinib+Capecitabine
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 339
- Registration Number
- NCT06313983
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT05407246
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Hemay007 800 mg QD groupDrug: Hemay007 1200 mg QD groupDrug: Hemay007 600 mg QD groupDrug: Hemay007 placebo group
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT05247216
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: PlaceboDrug: 60mg Hemay005
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 306
- Registration Number
- NCT04839328
- Locations
- 🇨🇳
Peking University People's Hospital, Peking, Beijing, China
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT04837235
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
- Prev
- 1
- 2
- 3
- Next